Biological parameters in major depression: Effects of paroxetine, viloxazine, moclobemide, and electroconvulsive therapy. Relation to early clinical outcome

Biological Psychiatry

Volumn 44, Issue 4, 1998, Pages 274-280

  Lestra, Catherine ^a   D'Amato, Thierry ^b   Ghaemmaghami, Chantal ^a   Perret Liaudet, Armand ^a   Broyer, Martine ^a   Renaud, Bernard ^a   Dalery, Jean ^b   Chamba, Geneviève ^c  

^a Groupement Hospitalier Edouard Herriot   (France)

^b Ctr Hosp Specialise Le Vinatier   (France)

^c UNIVERSITÉ LYON 1   (France)

Author keywords

Depression; Platelet monoamine oxidase activity; Serotonin T platelet content; Urinary B

Indexed keywords

BIOPTERIN; MOCLOBEMIDE; PAROXETINE; VILOXAZINE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DEPRESSION; EARLY DIAGNOSIS; ELECTROCONVULSIVE THERAPY; EVOLUTION; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; RATING SCALE; SEROTONINERGIC NERVE CELL; SYMPTOMATOLOGY; THROMBOCYTE ACTIVATION; TREATMENT OUTCOME;

ADRENERGIC UPTAKE INHIBITORS; ADULT; AGED; ANTIDEPRESSIVE AGENTS; BENZAMIDES; BIOLOGICAL MARKERS; BIOPTERIN; BLOOD PLATELETS; DEPRESSIVE DISORDER; DRUG RESISTANCE; ELECTROCONVULSIVE THERAPY; FEMALE; HUMANS; MALE; MIDDLE AGED; MOCLOBEMIDE; MONOAMINE OXIDASE; MONOAMINE OXIDASE INHIBITORS; PAROXETINE; PROSPECTIVE STUDIES; SEROTONIN; SEROTONIN UPTAKE INHIBITORS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; VILOXAZINE;

EID: 18244410775     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-3223(97)00389-2     Document Type: Article

References (32)

1. Abou-Saleh M.T., Anderson D.N., Collins J., Hughes K., Cattell R.J., Hamon C.G.B., et al. The role of pterins in depression and the effect of antidepressive therapy. Biol Psychiatry. 38:1995;458-463.
2. Anderson D.N., Abou-Saleh M.T., Collins J., Hughes K., Cattell R.J., Hamon C.G.B., et al. Pterin metabolism in depression An extension of the amine hypothesis and possible marker of response to ECT . Psychol Med. 22:1992;863-869.
3. Andondonskaja-Renz B., Zeitler H.I. Separation of pteridine from blood cells and plasma by reverse-phase high performance liquid chromatography. Anal Chem. 138:1983;68-78.
4. Aubin V., Jouvent R., Widlocher D., Darcourt G. Modélisation hypothétique du déficit sérotoninergique chez le sujet âgé L'Encéphale. 21:1993;37-46.
5. Blair J.A., Morar C., Hamon C.G.B., Al-Salihi J., Barford P.A., Pheasant A.E., et al. Tetrahydrobiopterin in depression. Lancet. ii:1984;163.
6. Bourin M., Ortega A., Larousse C. Viloxazine as a betamimetic antidepressant drug. Neuropsychobiology. 17:1987;35-40.
7. Celada P., Dolera M., Alvarez E., Artigas F. Effects of acute and chronic treatment with fluvoxamine on extracellular and platelet serotonin in the blood of major depressive patients. Relationship to clinical improvement. J Affect Disord. 25:1992;243-250.
8. Celada P., Perez J., Alvarez E., Artigas F. Monoamine oxidase inhibitors phenelzine and brofaromine increase plasma serotonin and decrease 5-hydroxyindoleacetic acid in patients with major depression Relationship to clinical improvement . J Clin Psychopharmacol. 12:1992;309-315.
9. Da Prada M., Kettler R., Keller H.H., Burkard W.P., Muggli-Maniglio, Haefely W.E. Neurochemical profile of moclobemide, a short-acting and reversible inhibitor of monoamine oxidase type A. J Pharmacol Exp Ther. 248:1989;400-414.
10. Feighner J.P., Cohn J.B., Fabre L.F., Fieve R.R., Mendels J., Shrivastava R.K., et al. A study comparing paroxetine placebo and imipramine in depressed patients. J Affect Disord. 28:1993;71-79.
11. Flachaire E., Beney C., Berthier A., Salandre J., Quincy C., Renaud B. Determination of reference values for serotonin concentration in platelets of healthy newborns, children, adults, and elderly subjects by HPLC with electrochemical detection. Clin Chem. 36:1990;2117-2121.
12. Garbutt J.C., Duch D.S., Nichol C.A., Woolf J.H. Urinary biopterin and neopterin excretion and pituitary adrenal activity in psychiatric patients. Psychiatry Res. 16:1985;181-187.
13. Gleiter C.H., Nilsson E., Mühlbauer B., Antonin K.H., Bieck P.R. Effect of the selective MAO-A inhibitors brofaromine, clorgyline and moclobemide on human platelet MAO-B activity. J Neural Transm. 89:1992;129-133.
14. Goodnick P.J., Henry J., Kumar A. Neurochemistry and paroxetine response in major depression. Biol Psychiatry. 37:1995;417-419.
15. Gupta R.N., Steiner M. Liquid chromatographic determination of inhibition of monoamine oxidase activity in platelet rich plasma of depressed patients treated with phenelzine. Clin Chim Acta. 152:1985;63-69.
16. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 12:1960;45-62.
17. Karege F., Widmer J., Bovier P., Gaillard J.M. Platelet serotonin and plasma tryptophan in depressed patients Effect of drug treatment and clinical outcome . Neuropsychopharmacology. 10:1994;207-214.
18. Mann J.J., McBride P.A., Anderson G.M., Mieczkowski T.A. Platelet and whole blood serotonin content in depressed inpatients Correlations with acute and life-time psychopathology . Biol Psychiatry. 32:1992;243-257.
19. Meltzer H.Y., Lowy M.T. The serotonin hypothesis of depression. Meltzer H.Y. Psychopharmacology, The Third Generation of Progress. 1987;513-526 Raven Press, New York.
20. Meltzer H.Y., Lowy M.T., Locascio J.J. Platelet MAO activity and the cortisol response to dexamethasone in major depression. Biol Psychiatry. 24:1988;129-142.
21. Muck-Seler D., Jakovljevic M., Deanovic Z. Effect of antidepressant treatment on platelet 5-HT content and relation to therapeutic outcome in unipolar depressive patients. J Affect Disord. 23:1991;157-164.
22. Oreland L., Hallman J. Monoamine oxidase activity in relation to psychiatric disorders The state of the art . Nord Psykiatr Tidsskr. 42:1988;95-105.
23. Pajer K. New strategies in the treatment of depression in women. J Clin Psychiatry. 56:(suppl 2):1995;30-37.
24. Poirier M.F., Loo H., Mitrani N., Benkelfat C., Askienazy S., Le Fur G. Platelet MAO activity in clinical subtypes of depression and DST suppression. Acta Psychiatr Scand. 75:1987;456-463.
25. Quan-Bui K.H.L., Plaisant O., Leboyer M., Gay C., Kamal L., Devynck A.M., et al. Reduced platelet serotonin in depression. Psychiatry Res. 13:1984;129-139.
26. Quintana J. Platelet serotonin and plasma tryptophan decreases in endogenous depression. Clinical, therapeutic and biological correlations. J Affect Disord. 24:1992;55-62.
27. Schalling D., Asberg M., Edman G., Oreland L. Markers for vulnerability to psychopathology Temperament traits associated with platelet MAO activity . Acta Psychiatr Scand. 76:1987;172-182.
28. Sheline Y.I., Bardgett M.E., Jackson J.L., Newcomer J.W., Csernansky J.G. Platelet serotonin markers and depressive symptomatology. Biol Psychiatry. 37:1995;442-447.
29. Sofuoglu S., Dogan P., Besim T., Bastürk M., Tanrikulu G. MAO-B activity in depression and anxiety disorders. Biol Psychiatry. 31:1992;634-638.
30. Van Kempen G.M.J., Notten P., Hengeveld M.W. Repeated measures of platelet MAO activity and 5-HT in group of suicidal women. Biol Psychiatry. 31:1992;529-530.
31. Waldmeier P.C., Graf T., Germer M., Feldtrauer J.J., Howald H. Serotonin uptake inhibition by the monoamine oxidase inhibitor brofaromine. Biol Psychiatry. 33:1993;373-379.
32. Widlöcher D. Retardation A basic emotional response . Davis J.M., Maas J.W. The Affective Disorders. 1983;165-181 American Psychiatric Press, Washington, DC.